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journal homepage: www.i jge-onl ine.comEditorialEarly Biomarkers for Neurodegenerative DisordersAt transition from symptomatic to course-modifying therapies
for neurodegenerative disorders, biomarkers play a crucial role
for identiﬁcation of patients with appropriate neurobiological tar-
gets. Biomarkers, therefore, have been becoming an essential part
of neuroscientiﬁc research1. A biomarker is ideally an indicator
that can be measured accurately, easily, and cheaply, preferably
with non-invasive techniques. In this issue, we appreciate Gozke
E et al's study “Visual Event Related Potentials in Patients with
Mild Cognitive Impairment” from Istanbul, Turkey2. Mild cognitive
impairment is one of the prodromal conditions for dementia. Event
related potentials are among themost frequently used examination
in neurophysiology, recorded from the scalp to provide information
of brain function. Although the present pre-symptomatic diagnoses
of neurodegenerative disorders mainly depend on the neuroimag-
ing modalities, Gozke E et al's study is still inspiring for relevant
research in the future. The commonly used neuro-imaging includes
those like positron emission tomography (PET) sensitive to amyloid
and structural MRI studies of gray matter atrophy3.
One important goal to apply these biomarkers is to make
possible that the disease-modifying treatments may achieve the
objective of signiﬁcantly delaying the symptomatic and disabling
development of neurodegenerative disorders. However, present
neuroimagingmeasures still face signiﬁcant challenges on clinically
acceptable sensitivity and speciﬁcity. For example, PET amyloid im-
aging may be able to identify cumulating amyloid, but there is the
risk of a false-positive result particularly in the elderly. At another
hand, neurodegenerative conditions are progressive in nature,
which mechanisms of progression in humans are largely unclear.
Research on those early biomarkers can contribute to improvinghttp://dx.doi.org/10.1016/j.ijge.2016.10.001
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BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).our understanding of mechanisms of disease progression and the
development of novel treatment targets.
Early biomarker investigations for neurodegenerative disorders
follow a similar way to the drug discovery research, that is, from
exploratory use in the prodromal stages to publication and
approval, and hopefully onward to the clinical adoption. Gozke E
et al's study provides one example of those efforts. Much further
work is still welcome anticipated from this kind of research to
advance biomarkers for neurodegenerative disorders.References
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